Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK fusion |
| Therapy | TRI-611 |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK fusion | lung non-small cell carcinoma | predicted - sensitive | TRI-611 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TRI-611 treatment resulted in tumor regression in subcutaneous and intracranial cell line xenograft models of ALK fusion-positive non-small cell lung cancer (Mol Cancer Ther (2025) 24 (10_Supplement): B064). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract B064: TRI-611, a selective, CNS-penetrant molecular glue degrader of ALK with anti-tumor activity against preclinical models of ALK-fusion positive non-small cell lung cancer including kinase inhibitor refractory tumors | Full reference... |